9Mo·

Breakthrough for tremor drug

$PRAX could be interesting today 👆


Shares in drug developer Praxis Precision Medicines rise 11.5% to 299.9 dollars in pre-market trading.


$PRAX announces that the US Food and Drug Administration (FDA) has given its experimental drug ulixacaltamide for the treatment of patients with essential tremor a "breakthrough" designation.


Breakthrough therapy designation is intended to expedite the development and review of drugs to treat a serious condition or unmet medical need.


I entered the stock market with a small risk position, let's see what happens. I plan to exit during the course of the day, according to the motto "Sell the good news".

I normally avoid pre-market entries unless there is price-moving news before the start of trading.


The following are also on the list for potential short-term trades today? Let's see if I can find an entry point $ZETA (+2,65 %)
$LUNR (-0,52 %)

10
Participez à la conversation